Drug intelligence / Profile preview

ciprofloxacin + neomycin + vancomycin

Development stage
Preclinical
Lead developer
Bayer
Modality
Small Molecules
Administration
Intravenous, Oral, Topical, Intraperitoneal, Ophthalmic
01

Overview

This is a combination of three antibiotics—ciprofloxacin, neomycin, and vancomycin. Each component has a distinct mechanism of action: - Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. - Neomycin is an aminoglycoside antibiotic that binds to the 30S subunit of the bacterial ribosome, causing misreading of mRNA and inhibiting protein synthesis. - Vancomycin is a glycopeptide antibiotic that inhibits cell wall synthesis in Gram-positive bacteria by binding to D-Ala-D-Ala terminus of cell wall precursor units. This combination would provide broad-spectrum antibacterial coverage against both Gram-positive (including resistant strains) and Gram-negative organisms. However, there are no widely recognized or approved pharmaceutical products containing all three agents together; combinations such as ciprofloxacin plus vancomycin have been studied for severe infections but not typically with neomycin included[1][2][7]. The use of multiple antibiotics together can increase risk for adverse effects such as nephrotoxicity or ototoxicity[3][5], and may profoundly alter gut microbiota if administered orally[4].

02

Targets

D-Ala-D-Ala (D-Ala-D-Ala terminus)Topo IV (Bacterial Topoisomerase IV)DNA gyraseBacterial Ribosome

Beyond the preview

Go deeper on ciprofloxacin + neomycin + vancomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciprofloxacin + neomycin + vancomycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call